



ASX Announcement

3rd July 2020

Change of Director's Interest – Appendix 3Y

Invex Therapeutics Ltd (Invex, ASX: IXC, or the Company) provide the following update in relation to Dr Jason Loveridge's relevant interest in securities held in the Company, as a result of participation in Tranche 2 of the Placement

Further details with respect to Dr Jason Loveridge's interest in securities are provided in the attached Appendix 3Y.

This release dated 3rd July has been authorised for lodgement to ASX by the Board of Directors of Invex Therapeutics and lodged by Narelle Warren, Company Secretary.

ENDS

Appendix 3Y

Change of Director's Interest Notice

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.

Introduced 30/09/01 Amended 01/01/11

Name of entity Invex Therapeutics Ltd
ABN 29 632 145 334

We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.

Name of Director	Dr Jason Loveridge
Date of last notice	2 June 2020

Part 1 - Change of director's relevant interests in securities

In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust

Note: In the case of a company, interests which come within paragraph (i) of the definition of "notifiable interest of a director" should be disclosed in this part.

Direct or indirect interest	Direct
Nature of indirect interest (including registered holder) Note: Provide details of the circumstances giving rise to the relevant interest.	
Date of change	3 July 2020
No. of securities held prior to change	3,336,000 ordinary shares – Dr Jason Loveridge 800,000 unlisted options exercisable at \$0.60 on or before 22 November 2023 subject to certain vesting conditions – Dr Jason Loveridge
Class	Ordinary shares
Number acquired	38,462
Number disposed	-
Value/Consideration Note: If consideration is non-cash, provide details and estimated valuation	\$50,001

+ See chapter 19 for defined terms.

No. of securities held after change	3,374,462 ordinary shares – Dr Jason Loveridge 800,000 unlisted options exercisable at \$0.60 on or before 22 November 2023 subject to certain vesting conditions – Dr Jason Loveridge
Nature of change Example: on-market trade, off-market trade, exercise of options, issue of securities under dividend reinvestment plan, participation in buy-back	Participation in Tranche 2 of Placement

Part 2 – Change of director's interests in contracts

Note: In the case of a company, interests which come within paragraph (ii) of the definition of "notifiable interest of a director" should be disclosed in this part.

Detail of contract	
Nature of interest	
Name of registered holder (if issued securities)	
Date of change	
No. and class of securities to which interest related prior to change Note: Details are only required for a contract in relation to which the interest has changed	
Interest acquired	
Interest disposed	
Value/Consideration Note: If consideration is non-cash, provide details and an estimated valuation	
Interest after change	

Part 3 – ⁺Closed period

Were the interests in the securities or contracts detailed above traded during a ⁺closed period where prior written clearance was required?	
If so, was prior written clearance provided to allow the trade to proceed during this period?	
If prior written clearance was provided, on what date was this provided?	

⁺ See chapter 19 for defined terms.